menu

The Role of Emerging Therapies for Retinal Disease in Clinical Practice

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Role of Emerging Therapies for Retinal Disease in Clinical Practice

4 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    This program will focus on the clinical trial and real-world data about the novel and emerging therapies for the treatment of dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, and diabetic macular edema and how these therapies may be integrated into real-world clinical practice.  

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Clinical and Patient Educators Association and iVista Medical Education, Inc.

  • Commercial Support

    This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc, Apellis Pharmaceuticals, Iveric Bio, and Outlook Therapeutics.

  • Target Audience

    This education is intended for retina specialists, ophthalmologists, and optometrists with an interest in the management of patients with dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, and diabetic macular edema retina. 

  • Educational Objectives

    After completing this activity, the participant should be better able to:

    1. Discuss the current limitations in therapeutic options for the treatment of dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, and retinal vein occlusion
    2. Review the clinical trial data on the emerging and current therapies for the treatment of dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, and retinal vein occlusion.
    3. Identify real-world experience and strategies to integrate novel therapies for dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, and retina vein occlusion into clinical practice
  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and iVista Medical Education, Inc.  CPEA is accredited by the ACCME to provide continuing medical education for physicians.

    Physician Credit Designation
    Clinical and Patient Educators Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • CPEA Contact Information

    For information about the accreditation of this program, please contact CPEA at 303-953-4580 or inquire@cpea-assn.org

  • Instructions for Obtaining Credit

    In order to receive credit, participants must also score at least a 75 % on the post-test and evaluation form.

  • Fee Information& Refund/Cancellation Policy

    There is no fee for this educational activity.

  • Disclosure of Conflicts of Interest

    Clinical and Patient Educators Association (CPEA) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by CPEA are required to disclose all financial relationships with any ineligible company within the past 24 months to CPEA.  All financial relationships reported are identified as relevant and mitigated by CPEA in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by CPEA to assure objectivity and that the activity is free of commercial bias. 

    All relevant financial relationships have been mitigated.

    The faculty have the following relevant financial relationships with ineligible companies:

    Rishi Singh
    Consulting Fee (e.g., Advisory Board): Regeneron, Genentech, Alcon, Bausch and Lomb, Asclepix, Gyroscope, Novartis, Apellis

    Christina Weng
    Consulting Fee (e.g., Advisory Board): Allergan/AbbVie, Alimera Sciences, Alcon, Novartis, DORC, Genentech, Regeneron, REGENXBIO, Iveric Bio
    Contracted Research (Principal Investigators must provide information, even if received by the institution): AGTC, Alimera Sciences, DRCR Retina Network

    Mark Barakat
    Consulting Fee (e.g., Advisory Board): AbbVie Inc, Adverum Biotech, Alcon, Alimera, Allegro, Allergan, Apellis, Arctic Vision, Bausch and Lomb, Biogen, CalciMedica, Clearside Biomedical, Coherus Biosciences, EyePoint Pharma, Genentech, Kodiak Sciences, Iveric Bio, Novartis, Ocular Therapeutix, Opthea, Outlook Therapeutics, Palatin Technologies, Regeneron, RegenxBio, RevOpsis Therapeutics, Roche, Stealth Biotherapeutics
    Contracted Research (Principal Investigators must provide information, even if received by the institution): Adverum Biotech, Annexon Biosciences, CalciMedica, Clearside Biomedical, EyePoint Pharma, Gemini Therapeutics, Genentech, Gyroscope Therapeutics, Kodiak Sciences, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxular, Oxurion, RegenxBio, ReNeuron, Ribomic, Roche, Stealth Biotherapeutics, Unity Biotechnology
    Speakers' Bureau: Apellis, Bausch and Lomb, Genentech, Iveric Bio, Novartis, Regeneron
    Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): NeuBase, Oxurion, RevOpsis Therapeutics

    Arshad Khanani
    Consulting Fee (e.g., Advisory Board): Adverum, Aerpio, Alimera, Allergan, Apellis, Asclepix, Aviceda, Bausch and Lomb, Broadwing Bio, Chengdu Kanghong, Cholgene, 4DMT, Dutch Ophthalmic Research Center, Gemini, Genentech, Glaukos, Graybug, Gyroscope, Iveric Bio, Janssen, Kato Pharma, Kodiak, Oculis, Opthea, Oxurion, Novartis, Polyphotonix, Recens Medical, Regeneron, Retrotope, Regenxbio, Roche, Surrozen, Thea, Unity Bio
    Contracted Research (Principal Investigators must provide information, even if received by the institution): Adverum, Apellis, Asclepix, Chengdu Kanghong, 4DMT, Gemini, Genentech, Graybug Vision, Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio, Ocular Therapeutix, Oculis, Opthea, Oxurion, Novartis, Recens Medical, Regenxbio, Roche, Unity Bio
    Speakers' Bureau: Allergan, Genentech, Novartis
    Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Aviceda, Recens Medical, Retrotope, Polyphotonix

    The planners and managers have the following relevant financial relationships with ineligible companies:

    Andrea Funk
    Nothing to disclose

    Liddy Knight
    Nothing to disclose

    Yaremi Koopot
    Nothing to disclose

    Alana Ochoa
    Nothing to disclose

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Clinical and Patient Educators Association (CPEA) and iVista Medical Education, Inc do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    This program will focus on the clinical trial and real-world data about the novel and emerging therapies for the treatment of dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, and diabetic macular edema and how these therapies may be integrated into real-world clinical practice.  

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Clinical and Patient Educators Association and iVista Medical Education, Inc.

  • Commercial Support

    This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc, Apellis Pharmaceuticals, Iveric Bio, and Outlook Therapeutics.

  • Target Audience

    This education is intended for retina specialists, ophthalmologists, and optometrists with an interest in the management of patients with dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, and diabetic macular edema retina. 

  • Educational Objectives

    After completing this activity, the participant should be better able to:

    1. Discuss the current limitations in therapeutic options for the treatment of dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, and retinal vein occlusion
    2. Review the clinical trial data on the emerging and current therapies for the treatment of dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, and retinal vein occlusion.
    3. Identify real-world experience and strategies to integrate novel therapies for dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, and retina vein occlusion into clinical practice
  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and iVista Medical Education, Inc.  CPEA is accredited by the ACCME to provide continuing medical education for physicians.

    Physician Credit Designation
    Clinical and Patient Educators Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • CPEA Contact Information

    For information about the accreditation of this program, please contact CPEA at 303-953-4580 or inquire@cpea-assn.org

  • Instructions for Obtaining Credit

    In order to receive credit, participants must also score at least a 75 % on the post-test and evaluation form.

  • Fee Information& Refund/Cancellation Policy

    There is no fee for this educational activity.

  • Disclosure of Conflicts of Interest

    Clinical and Patient Educators Association (CPEA) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by CPEA are required to disclose all financial relationships with any ineligible company within the past 24 months to CPEA.  All financial relationships reported are identified as relevant and mitigated by CPEA in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by CPEA to assure objectivity and that the activity is free of commercial bias. 

    All relevant financial relationships have been mitigated.

    The faculty have the following relevant financial relationships with ineligible companies:

    Rishi Singh
    Consulting Fee (e.g., Advisory Board): Regeneron, Genentech, Alcon, Bausch and Lomb, Asclepix, Gyroscope, Novartis, Apellis

    Christina Weng
    Consulting Fee (e.g., Advisory Board): Allergan/AbbVie, Alimera Sciences, Alcon, Novartis, DORC, Genentech, Regeneron, REGENXBIO, Iveric Bio
    Contracted Research (Principal Investigators must provide information, even if received by the institution): AGTC, Alimera Sciences, DRCR Retina Network

    Mark Barakat
    Consulting Fee (e.g., Advisory Board): AbbVie Inc, Adverum Biotech, Alcon, Alimera, Allegro, Allergan, Apellis, Arctic Vision, Bausch and Lomb, Biogen, CalciMedica, Clearside Biomedical, Coherus Biosciences, EyePoint Pharma, Genentech, Kodiak Sciences, Iveric Bio, Novartis, Ocular Therapeutix, Opthea, Outlook Therapeutics, Palatin Technologies, Regeneron, RegenxBio, RevOpsis Therapeutics, Roche, Stealth Biotherapeutics
    Contracted Research (Principal Investigators must provide information, even if received by the institution): Adverum Biotech, Annexon Biosciences, CalciMedica, Clearside Biomedical, EyePoint Pharma, Gemini Therapeutics, Genentech, Gyroscope Therapeutics, Kodiak Sciences, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxular, Oxurion, RegenxBio, ReNeuron, Ribomic, Roche, Stealth Biotherapeutics, Unity Biotechnology
    Speakers' Bureau: Apellis, Bausch and Lomb, Genentech, Iveric Bio, Novartis, Regeneron
    Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): NeuBase, Oxurion, RevOpsis Therapeutics

    Arshad Khanani
    Consulting Fee (e.g., Advisory Board): Adverum, Aerpio, Alimera, Allergan, Apellis, Asclepix, Aviceda, Bausch and Lomb, Broadwing Bio, Chengdu Kanghong, Cholgene, 4DMT, Dutch Ophthalmic Research Center, Gemini, Genentech, Glaukos, Graybug, Gyroscope, Iveric Bio, Janssen, Kato Pharma, Kodiak, Oculis, Opthea, Oxurion, Novartis, Polyphotonix, Recens Medical, Regeneron, Retrotope, Regenxbio, Roche, Surrozen, Thea, Unity Bio
    Contracted Research (Principal Investigators must provide information, even if received by the institution): Adverum, Apellis, Asclepix, Chengdu Kanghong, 4DMT, Gemini, Genentech, Graybug Vision, Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio, Ocular Therapeutix, Oculis, Opthea, Oxurion, Novartis, Recens Medical, Regenxbio, Roche, Unity Bio
    Speakers' Bureau: Allergan, Genentech, Novartis
    Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Aviceda, Recens Medical, Retrotope, Polyphotonix

    The planners and managers have the following relevant financial relationships with ineligible companies:

    Andrea Funk
    Nothing to disclose

    Liddy Knight
    Nothing to disclose

    Yaremi Koopot
    Nothing to disclose

    Alana Ochoa
    Nothing to disclose

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Clinical and Patient Educators Association (CPEA) and iVista Medical Education, Inc do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule4 Jun 2023